13 resultater
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to assay methods for detecting levels of specific enzymes in biological samples. More particularly, the present invention relates to methods for the detection of Matrix Metallo-Proteinase No. 9 (hereinafter "MMP"
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a method of using hydrophobic tetracycline for the inhibition of serine proteinase activity in biological systems. The invention more particularly relates to a therapeutic use of a 4-de(dimethylamino)tetracycline to treat
FIELD OF INVENTION
The present invention relates in its broadest aspect to the field of treatment and prevention of diseases and to the cosmetic field, in particular the pharmaceutical and cosmetic use of serine proteinases derived from fish. Specifically there are provided pharmaceutically or
FIELD OF THE INVENTION
This invention relates to N-hydroxylated vanilloid fatty amides and N-hydroxylated vanilloid fatty carbamates and their use as anti-inflammatory pharmaceuticals. Methods for preparing these substances are also described.
BACKGROUND OF THE INVENTION
Inflammation is a clinically
BACKGROUND OF THE INVENTION
Interleukin-1.beta. (IL-1.beta.) is a major mediator of chronic and acute inflammation. Along with IL-1.beta., human monocytes produce two additional members of the IL-1 gene family; interleukin-1.alpha. (IL-1.alpha.) and IL-1 receptor antagonist (IL-RA). All three
BACKGROUND OF THE INVENTION
Interleukin-1.beta. (IL-1.beta.) is a major mediator of chronic and acute inflammation. Along with IL-1.beta., human monocytes produce two additional members of the IL-1 gene family; interleukin-1.alpha. (IL-1.alpha.) and IL-1 receptor antagonist (IL-RA). All three
BACKGROUND OF THE INVENTION
Interleukin-1.beta. (IL-1.beta.) is a major mediator of chronic and acute inflammation. Along with IL-1.beta., human monocytes produce two additional members of the IL-1 gene family; interleukin-1.alpha. (IL-1.alpha.) and IL-1 receptor antagonist (IL-RA). All three
BACKGROUND OF THE INVENTION
Interleukin-1.beta. (IL-1.beta.) is a major mediator of chronic and acute intimation. Along with IL-1.beta., human monocytes produce two additional members of the IL-1 gene family; interleukin-1.alpha. (IL-1.alpha.) and IL-1 receptor antagonist (IL-RA). All three proteins
INTRODUCTION
Cytokines of the interleukin 1 family (IL-1) play a major role in a large number of autoimmune, infectious and inflammatory diseases (Sims J E and Smith D E, Nature Rev Immunology 2010). Interleukin 33 (IL-33), initially named NF-HEV, is a new cytokine of the IL-1 family comprising 270
FIELD OF THE INVENTION
THIS INVENTION relates to a metalloprotease that mediates proteolytic cleavage of proteins located at the cell surface. More particularly, this invention relates to ADAM 10 and/or ADAM17 metalloprotease-mediated proteolytic cleavage of substrate proteins, such as ligands for